# To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease

> **NCT04143958** · PHASE4 · WITHDRAWN · sponsor: **Sanofi**

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** agalsidase beta (GZ419828)
- **DRUG:** agalsidase alfa

## Key facts

- **NCT ID:** NCT04143958
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09
- **Primary completion:** 2023-11
- **Final completion:** 2023-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The Sponsor terminated the study due to recruitment infeasibility without having enrolled any patient.
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04143958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04143958, "To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04143958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*